Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)

v3.25.1
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Research and development expense $ 7,269,146 $ 5,799,518
General and administrative expense 4,782,060 5,657,543
Interest income, net (201,088) (335,541)
Net Loss (11,850,118) (11,121,520)
Reportable Segment, Aggregation before Other Operating Segment [Member]    
Segment Reporting Information [Line Items]    
Preclinical, clinical trial and other costs 5,450,963 3,817,669
Administrative and facilities expense [1] 2,800,304 3,919,751
Interest income, net (201,088) (335,541)
Net Loss 11,850,118 11,121,520
Reportable Segment, Aggregation before Other Operating Segment [Member] | Employees [Member]    
Segment Reporting Information [Line Items]    
Research and development expense [2] 1,818,183 1,981,849
General and administrative expense [3] $ 1,981,756 $ 1,737,792
[1] Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.
[2] Research and development personnel costs include employee stock-based compensation expense of $169,414 and $363,956 for the year ended December 31, 2024, and 2023, respectively.
[3] General and administrative personnel costs include employee stock-based compensation expense of $186,925 and $387,854 for the year ended December 31, 2024, and 2023, respectively, and are net of reimbursements received from CorLyst, LLC.